Tumor necrosis factor alpha (TNF-␣) is overexpressed during human immunodeficiency virus (HIV) infection. RP 55778, a TNF-␣ synthesis inhibitor, decreases HIV replication in monocytes/macrophages. Therapeutic use of RP 55778 in vivo, like that of other biological response modifiers, would theoretically require association with dideoxynucleosides. We have evaluated here the combinatory effects of zidovudine (AZT) or dideoxyinosine (ddI) and RP 55778. This TNF-␣ inhibitor antagonizes the antiviral effects of both dideoxynucleosides, especially AZT. The more favorable anti-HIV activity of ddI in resting cells may explain these unequal degrees of antagonism.
Tumor necrosis factor alpha (TNF-␣) is detected in sera of human immunodeficiency virus (HIV)-infected patients (2, 8, 16 ) and simian immunodeficiency virus-infected monkeys (6) and sometimes in culture supernatants of HIV-1-infected monocytes/macrophages (MM) (9) . Otherwise, TNF-␣ is capable of increasing HIV gene expression and replication by intracellular activation and autocrine and paracrine pathways (12, 14) . Hence, the regulation of TNF expression is considered a new pharmacological anti-HIV tool. Like pentoxifylline, RP 55778
, a platelet-activating factor receptor antagonist inhibiting TNF-␣ synthesis, has demonstrated in vitro anti-HIV effects in chronically infected promonocytic cells (15) and in HIV-1-infected MM (9) . In vivo, like other biological response modifiers, RP 55778 would theoretically be used as an adjunct to antivirals, such as dideoxynucleosides (ddN). However, because its anti-TNF abilities could decrease the state of MM differentiation and the anabolic phosphorylation to active ddN triphosphate, it was of interest to investigate the effects of RP 55778 on the antiviral activities of zidovudine (AZT) and dideoxyinosine (ddI). Here, we have studied these combinations in 7-day-differentiated MM isolated by countercurrent centrifugal elutriation (10) . MM were pretreated with three doses of each molecule for 1 h (10, 50, and 100 M RP 55778; 10, 50, and 100 nM AZT; 0.3, 1.5, and 3 M ddI); culture medium and compounds were then renewed twice a week. One million of these cells were infected by 10,000 50% tissue culture infectious doses of a primary macrophagetropic HIV isolate, HIV-1-DAS (3). Antiviral activities were quantified by the inhibition of the production of reverse transcriptase (RT) activity in MM culture supernatants (13) . RT activity was measured all along the MM cultures when cell culture medium was renewed. Cumulative RT activity was used to calculate the percentages of control RT activity and the 50% effective doses (ED 50 ). The combined effects were analyzed by using either the combination index (CI) with J. and T. C. Chou's microcomputer software (4, 5) or the fractional inhibitory concentration (FIC) index (1). For median effect plots, the mutually nonexclusive equation was used.
HIV-1-DAS replication started at about 12 days and peaked on day 23 after viral exposure (Fig. 1) . Under our experimental conditions, AZT and ddI demonstrated antiviral effects (Fig.  2) , and granulocyte-macrophage colony-stimulating factor slightly antagonized these activities (data not shown). ED 50 of AZT and ddI were 5 and 50 nM, respectively. The unequal anti-HIV activities of these two ddN are consistent with previously published data (11) . RP 55778 was also found to display potent inhibitory effects on HIV-1-DAS replication (ED 50 ϭ 50 M). On the other hand, RP 55778 reduced the antiviral activities of AZT and ddI. The CI, determined by the method of Chou and Talalay, was always higher than 1.0 (Fig. 3) . Moreover, the second analysis, using the FIC index, confirmed these antagonistic effects of RP 55778 against ddN antiviral activities. The FIC indices of the AZT-RP 55778 and ddI-RP 55778 combinations were 221 and 35, respectively. In both analyses, the degree of antagonism between RP 55778 and AZT was different from that between RP 55778 and ddI. The effects of RP 55778 may be less deleterious on the antiviral potential of ddI. Although ddI and AZT have a common mechanism of anti-HIV activity, they have different anabolic phosphorylation profiles, which determine the ratio of ddN triphosphate to normal deoxynucleoside triphosphate and the antiviral potential in resting and activated cells (7) . Thus, ddI exerts anti-HIV activity more favorably in resting cells, while AZT preferentially protects activated cells against HIV infection. These differences could explain the unequal degrees of antagonism, since RP 55778 could lessen the activation state by reducing TNF-␣ production. The quantification of intracellular monophosphate metabolites of AZT and ddI under our experimental conditions confirmed that phosphorylation of AZT and ddI is dependent on cell activation and is altered by RP 55778 (data not shown), but no differences were observed between the two dideoxynucleosides.
These in vitro data are not necessarily predictive of the in vivo antiviral efficacies of these combinations, but they may be useful for estimating the drug interactions and potency of molecule combinations. Moreover, these data justify the evaluation of drug combinations in appropriate animal models, such as simian immunodeficiency virus-infected macaques, prior to the initiation of clinical trials.
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